When the Delfi technology was used as a pre-screen to determine if a low dose CT (LDCT), should be performed, the combined approach led to the detection of 90% of lung cancers, including 80% of stage I cancers
A treatment to prevent extreme symptoms and cut hospitalisation
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The company is doubling its chemistry research capacity that should commission by Q2'FY22
Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
Subscribe To Our Newsletter & Stay Updated
